Menu
Search Close

News

Helium Special Situations increases interest in Scancell

17th November 2011

Holdings in Company

 The Company announces that it has received notification that Helium Special Situations Fund Limited has increased its beneficial interest in Scancell Holdings to 17,586,940 ordinary shares of 0.1 pence each which represents approximately 9.06 per cent of the issued capital of the Company.

 For further information contact:

 Scancell Holdings Plc 

Professor Lindy Durrant/Dr Richard Goodfellow

+ 44 (0)207 245 1100

 

Hansard Communications- Financial PR 

Adam Reynolds/Guy McDougall

+ 44 (0)207 245 1100

 

Zeus Capital - Nominated Adviser

Ross Andrews/Tom Rowley

+ 44 (0)161 831 1512

 

XCAP Securities Plc - Broker

Jon Belliss/ Adrian Kirk

+44 (0) 207 101 7070

Webcasts, Interviews and Media Coverage

New Scancell chief sets out his vision to commercialise groundbreaking cancer treatments

Cliff Holloway, chief executive of Scancell Holdings Plc (LON:SCLP), spoke to Proactive soon after taking over as CEO at the immuno-oncology company.

Holloway says generating clinical data's a big focus for them in the near-term.

''Over the next two years we expect to see clinical readouts from two of our programmes - SCIB1 and Modi-1''.

''We'll be extending our pipeline particularly around Moditope with the Modi-3 programme, if we're successful with the grand challenge''.

''Then it's around looking at technical partnerships that will allow us to de-risk our developments''.

Thu, 15 Feb 2018 12:38:00

Scancell to work with Dutch firm on first product for Moditope cancer immuno-therapy platform

Dutch group ISA Pharmaceutical will incorporate its Amplivant technology into Modi-1, the first cancer treatment candidate being developed on the platform

Thu, 15 Feb 2018 15:00:00

Scancell drug receives positive write-up in leading journal as company updates on survival data

Immuno-therapy SCIB1, which is expected to progress into Phase II clinical trials in the second-half of the year, was the focus of a peer-reviewed paper in OncoImmunology

Mon, 12 Feb 2018 11:50:00